Rutgers Cancer Institute | Strategic Alliance Partners

For the first time, researchers sought to analyze the outcomes of pregnant women with r/r lymphoma based on the timing of the pregnancy and type of lymphoma.

Panelists review data behind the combination of tafasitamab and lenalidomide in relapsed/refractory diffuse large B-cell lymphoma.

Focused discussion on specific patient or disease factors that aid in the selection of therapy for patients with relapsed/refractory diffuse large B-cell lymphoma.

Key opinion leaders share a broad perspective on relapsed/refractory diffuse large B-cell lymphoma and the current treatment landscape.

Expert panelists open their discussion on diffuse large B-cell lymphoma by reflecting on diagnostic strategies and the frontline treatment armamentarium.

Sanjay Goel, MD, MS, discusses the preliminary efficacy of tinengotinib monotherapy in advanced solid tumors according to data from a phase 1b/2 trial (NCT04742959).

Eugenia Girda, MD, FACOG, discusses the use of pembrolizumab plus chemotherapy for patients with endometrial cancer as seen in the phase 3 NRG-GY018 trial.

Coral O. Omene, MD, PhD, discusses the need to improve early access to breast cancer screenings for patients in underserved populations and recent updates to the National Comprehensive Cancer Network Guidelines on breast cancer screening.

Coral O. Omene, MD, PhD, discusses the importance of a multidisciplinary, patient-focused approach to mitigating disparities in the care of patients with breast cancer.

Saum Ghodoussipour, MD, shares how some facilities in the tri-state region including Rutgers Cancer Institute and Robert Wood Johnson University Hospital, use enhanced blue light technology with an imaging solution that better highlights cancerous tumors in the bladder.

Researchers, including those at Rutgers Cancer Institute of New Jersey, are currently working to understand ethnic disparities in skin-cancer related morbidity and mortality in melanoma.

Clinical trials have strikingly low rates of Black participants, even those centered on diseases that disproportionately affect Black women in particular, such as breast cancer, the most commonly diagnosed cancer and the leading cause of cancer death for this population.

Though testicular cancer can impact males of any age, it generally affects men in their 20s and 30s. The average age at the time of diagnosis of testicular cancer is about 33, according to the American Cancer Society.

With a National Cancer Institute grant, investigators from Rutgers Cancer Institute of New Jersey and Georgetown University’s Lombardi Comprehensive Cancer Center will work to close racial disparity gaps in cancer care delivery by examining a novel approach to genetic testing and care based on community identified needs.

David D'Ambrosio, MD, discusses the benefit of utilizing adjuvant accelerated partial breast irradiation, as well as a phase 2 trial investigating robotic stereotactic adjuvant accelerated partial breast irradiation for hormone receptor–positive, postmenopausal, early-stage breast cancer.

Experts in hematologic malignancies conclude their discussion by discussing BTK degraders and other targets in the treatment of mantle cell lymphoma.

M. Michele Blackwood, MD, FACS, discusses the implementation of the phase 2 I-SPY 2 trial in breast cancer at Robert Wood Johnson Medical Center.

A comprehensive look at the role of bispecific antibodies, including glofitamab, in the treatment of mantle cell lymphoma.

Bijal D. Shah, MD, and Matthew J. Matasar, MD, discuss how they approach treating patients with MCL who rapidly progress on BTK inhibitors.

Prateek Gulhati, MD, PhD, discusses current treatment approaches in pancreatic cancer and strategies under investigation within the space.

Sanjay Goel, MD, MS, discusses the evolution of precision and personalized medicine in cancer care.

A panel of experts in hematologic malignancies analyze clinical studies and real-world data of brexucabtagene autoleucel in mantle cell lymphoma.

Alexey V. Danilov, MD, PhD, presents a second patient profile of a 60-year-old patient with MCL, and the panel discusses using CAR T-cell therapy to treat MCL.

A comprehensive discussion on ways to approach treating patients with high-risk mantle cell lymphoma.

A detailed look at how to select the appropriate BTK inhibitor to treat patients with MCL and the potential role of the non-covalent BTK inhibitor pirtobrutinib in MCL.

Howard S. Hochster, MD, discusses the evaluation of trastuzumab and pertuzumab vs cetuximab and irinotecan in HER2-amplified metastatic colorectal cancer.

Experts in hematologic malignancies review the role of BTK inhibitors and other therapies in patients with relapsed/refractory mantle cell lymphoma.

A panel of experts in hematologic malignancies discuss the SHINE study, which looked at ibrutinib with bendamustine and rituximab in elderly patients with MCL.

Mridula George, MD, discusses the methods used to evaluate cardiotoxicity associated with adjuvant trastuzumab emtansine plus concurrent radiation therapy, and explains implications on the use of trastuzumab emtansine plus radiation in patients with early-stage HER2-positive breast cancer.

Mridula George, MD, discusses the evaluation of cardiotoxicity associated with adjuvant trastuzumab emtansine with concurrent radiotherapy in patients with HER2-positive breast cancer.